Virus News and Research

Latest Virus News and Research

Novel interventions for New World hemorrhagic fevers needed

New World hemorrhagic fevers are emerging infectious diseases found in South America that can cause terrible, Ebola-like symptoms. Current treatments are expensive and only partially effective.

9 Mar 2010

New reservoir for hidden HIV-infected cells identified

University of Michigan scientists have identified a new reservoir for hidden HIV-infected cells that can serve as a factory for new infections. The findings, which appear online March 7 in Nature Medicine, indicate a new target for curing the disease so those infected with the virus may someday no longer rely on AIDS drugs for a lifetime.

9 Mar 2010

DermaGenoma releases The HerpesDX Genetic Test for Frequent Genital Herpes

Molecular dermatology research and development innovator DermaGenoma, Inc. today released The HerpesDX Genetic Test for Frequent Genital Herpes. The new screening test will help doctors assess patients’ risk for developing frequent Genital Herpes (HSV-2) outbreaks.

9 Mar 2010

NOVAVAX' Stage B 2009 H1N1 VLP pandemic influenza vaccine study in Mexico: Enrollment complete

Novavax, Inc. announced today that the enrollment of over 3,500 subjects in Mexico has been completed in Stage B of its pivotal 2009 H1N1 virus-like-particle (VLP) pandemic influenza vaccine study. With the 1,000 subjects already enrolled in Stage A of the trial, the enrollment in this pivotal trial is now complete with over 4,500 subjects.

8 Mar 2010

U-M scientists identify new reservoir for hidden HIV-infected cells that can serve as factory for new infections

8 Mar 2010

Investigators disprove reports that well-fed children are more vulnerable to dengue virus

A new study led by St. Jude Children's Research Hospital investigators disproves reports that well-fed children are more vulnerable to the dengue virus. Mosquitoes spread the virus, which can cause severe flu-like symptoms and sometimes lethal complications.

5 Mar 2010

NanoViricides files Universal Form S-3 Shelf Registration with SEC

NanoViricides, Inc., reports that it has filed a “Universal Form S-3 Shelf Registration” with the Securities and Exchange Commission for the sale from time to time of up to $40 million of its securities. The Company recently became eligible to file a shelf registration to register its securities.

5 Mar 2010

FDA's PADAC meeting to review pirfenidone NDA: InterMune posts briefing documents

InterMune, Inc. announced today that the U.S. Food and Drug Administration (FDA) has posted briefing documents for the March 9 Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting to review the New Drug Application (NDA) for pirfenidone, InterMune's investigational drug candidate for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function. The proposed trade name for pirfenidone is Esbriet®.

5 Mar 2010

Gluten intolerance: Hereditary risk factors and link to virus infections

A research project in the Academy of Finland's Research Programme on Nutrition, Food and Health (ELVIRA) has brought new knowledge on the hereditary nature of gluten intolerance and identified genes that carry a higher risk of developing the condition. Research has shown that the genes in question are closely linked with the human immune system and the occurrence of inflammations, rather than being connected with the actual breakdown of gluten in the digestive tract.

5 Mar 2010

‘Testing Millions’ World AIDS Day campaign surpasses its goal by testing more than 4.2M people for HIV

Testing Millions,’ a groundbreaking global effort led by AIDS Healthcare Foundation to test millions of people for HIV as part of a global testing campaign tied to the recent observance of World AIDS Day (December 1st) has far surpassed its goal by testing more than 4.2 million people for HIV and identifying more than 110,106 HIV-positive individuals in 23 countries around the world.

5 Mar 2010

Common allergens that may cause contact dermatitis

Itchy irritated skin can leave some people scratching their heads trying to determine the cause of this bothersome condition. What did they touch? Is it just dry skin gone awry? Are they allergic to something in their home or workplace? The answers to these questions could require not only a little detective work, but the help of a dermatologist who can diagnose and treat the most likely culprit - contact dermatitis.

5 Mar 2010

South West Liver Unit researchers receive grants for developing Hepatitis C vaccine

Researchers at the South West Liver Unit, based at Plymouth Hospitals NHS Trust and supported by the Peninsula Medical School, are working to save more lives and improve the health of Hepatitis C sufferers around the world by developing a vaccine for the disease.

5 Mar 2010

Chikungunya: Experimental vaccine successfully tested in monkeys

Imagine a mosquito-borne virus that has already infected millions of people in recent outbreaks in South and Southeast Asia, the islands of the Indian Ocean, Africa and northern Italy. Although seldom fatal, it causes highly painful arthritis-like symptoms that can linger for months or even years. It's capable of adapting to spread through a mosquito species common in much of North America. And no vaccine or treatment exists to protect humans from its effects.

5 Mar 2010

Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented

Data evaluating the efficacy and safety of STELARA™ (ustekinumab) and REMICADE® (infliximab) in patients with plaque psoriasis who had an inadequate response to Enbrel® (etanercept) will be presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) in Miami, Fla., from March 5-9, 2010.

5 Mar 2010

Risk of MS increases by many folds following infection with EBV: Study

Researchers from the Harvard School of Public Health, Walter Reed Army Institute of Research, and a team of collaborators have observed for the first time that the risk of multiple sclerosis (MS) increases by many folds following infection with the Epstein-Barr virus (EBV).

5 Mar 2010

Argos Therapeutics' AGS-004 immunotherapy for HIV demonstrates clinical and commercial potential

Argos Therapeutics today announced the publication of a manuscript in the February edition of Clinical Immunology, detailing positive immune response, safety and manufacturing data for its AGS-004 immunotherapy for HIV. AGS-004 is a product of the Company’s Arcelis™ technology, and is a personalized, RNA-loaded dendritic cell-based immunotherapy that is perfectly matched to each patient’s unique HIV viral burden. The manuscript details a clinical study in which AGS-004 was evaluated in type-1 HIV-infected adults who were being treated with antiretroviral therapy (ART).

5 Mar 2010

BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine

BioVex Inc, a private biotechnology company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that the first subject had been dosed in the Phase 1 study of its live attenuated genital herpes vaccine, ImmunoVEXHSV2. The Phase 1 study is an open label ascending dose trial, assessing safety and immune response in healthy volunteers. The study is taking place in the UK at the Chelsea and Westminster Hospital in London and will involve up to 42 already identified subjects.

4 Mar 2010

Alnylam Pharmaceuticals asks Court to dismiss MIT from any claims for monetary damages in ongoing litigation

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the company and Max Planck have asked the Court to dismiss the Massachusetts Institute of Technology from any claims for monetary damages in the ongoing litigation related to the Tuschl I patent series.

4 Mar 2010

Mosaic vaccines show promise in reducing HIV spread

Two teams of researchers-including Los Alamos National Laboratory theoretical biologists Bette Korber, Will Fischer, Sydeaka Watson, and James Szinger-have announced an HIV vaccination strategy that has been shown to expand the breadth and depth of immune responses in rhesus monkeys. Rhesus monkeys provide the best animal model currently available for testing HIV vaccines.

4 Mar 2010

TNFerade's suppression of cancer metastases: Mechanisms revealed

GenVec, Inc. announced the publication of new preclinical research revealing mechanisms by which TNFerade(TM) suppresses cancer metastases through activation of the immune system.

4 Mar 2010

Virus News and Research

Latest Virus News and Research

Novel interventions for New World hemorrhagic fevers needed

New reservoir for hidden HIV-infected cells identified

DermaGenoma releases The HerpesDX Genetic Test for Frequent Genital Herpes

NOVAVAX' Stage B 2009 H1N1 VLP pandemic influenza vaccine study in Mexico: Enrollment complete

U-M scientists identify new reservoir for hidden HIV-infected cells that can serve as factory for new infections

Investigators disprove reports that well-fed children are more vulnerable to dengue virus

NanoViricides files Universal Form S-3 Shelf Registration with SEC

FDA's PADAC meeting to review pirfenidone NDA: InterMune posts briefing documents

Gluten intolerance: Hereditary risk factors and link to virus infections

‘Testing Millions’ World AIDS Day campaign surpasses its goal by testing more than 4.2M people for HIV

Common allergens that may cause contact dermatitis

South West Liver Unit researchers receive grants for developing Hepatitis C vaccine

Chikungunya: Experimental vaccine successfully tested in monkeys

Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented

Risk of MS increases by many folds following infection with EBV: Study

Argos Therapeutics' AGS-004 immunotherapy for HIV demonstrates clinical and commercial potential

BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine

Alnylam Pharmaceuticals asks Court to dismiss MIT from any claims for monetary damages in ongoing litigation

Mosaic vaccines show promise in reducing HIV spread

TNFerade's suppression of cancer metastases: Mechanisms revealed

A new way of characterising biomolecules eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in